Elutia (ELUT) Stock Price, News & Analysis

Company Overview

Elutia Inc. (NASDAQ: ELUT) is a medical technology company focused on developing and commercializing biologic and drug-eluting products for regenerative medicine and implantable medical devices. Its technologies are designed to support tissue healing, improve the performance of implanted devices and address clinical needs in areas including cardiac care and orthopedics.

The company’s product portfolio has included the CanGaroo family of biologic envelopes, which are used to help manage and protect implantable electronic devices such as pacemakers and defibrillators. Elutia has also developed biologic products intended to support bone repair and regeneration, along with pipeline products that combine implantable devices with therapeutic agents.

Elutia was formerly known as Aziyo Biologics and adopted its current name as it refined its focus on drug-eluting implants and regenerative medicine. The company primarily serves healthcare providers and medical-device markets in the United States, with its products distributed through commercial and clinical channels.

Key Stats

• Today's Range: $0.79 to $0.81
• 50-Day Range: $0.79 to $1.01
• 52-Week Range: $0.50 to $1.39
• Volume: 4.72 million shs
• Average Volume: 28,657 shs
• Market Capitalization: $35.43 million
• P/E Ratio: 0.84
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Elutia Stock Analysis - MarketRank™

Elutia scored higher than 30% of companies evaluated by MarketBeat, and ranked 759th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Elutia has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Elutia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elutia is 0.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elutia is 0.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.64.

Price to Book Value per Share Ratio

Elutia has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Elutia has been sold short.

Short Interest Ratio / Days to Cover

Elutia has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elutia has recently decreased by 51.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elutia does not currently pay a dividend.

Dividend Growth

Elutia does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.39

News Sentiment

Elutia has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Elutia this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elutia insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ELUT
• CIK: 1708527
• Web: www.elutia.com
• Phone: (240) 247-1143
• Fax: 510-307-9896
• Employees: 180
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.95
• Trailing P/E Ratio: 0.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $53.38 million
• Net Margins: 426.93%
• Pretax Margin: -184.24%
• Return on Equity: -407.37%
• Return on Assets: -47.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $12.29 million
• Price / Sales: 2.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 44,290,000
• Free Float: 36,406,000
• Market Cap: $35.43 million
• Optionable: Not Optionable
• Beta: 0.84